A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis | MicrobiomeTrials← Back to trialsNCT07330934
A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
TERMINATEDPHASE2INTERVENTIONAL
Trial Details
Start: 2025-12-31Est. Completion: 2026-08-18
Enrollment target: 18 participants Locations- Peking University People's Hospital, Beijing, Beijing Municipality, China
Other microbiome trials you might be interested in
AsthmaAsthma in ChildrenAllergyRhinitis, AllergicAtopic DermatitisAllergen Immunotherapy
The summary is available at --\> https://www.finnatopy.fi/summary
Tampere, FinlandCompleted Dec 2032
Food Allergy in Children
The aim is to study whether a multiallergen oral immunotherapy (OIT) strategy with slow up-dosing and low treatment dose…
Multiple LocationsEst. completion Dec 2032